Seeking Alpha

Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a...

Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a worldwide license and development agreement with Endo Pharmaceuticals (ENDP) for the rights to commercialize chronic pain treatment BEMA Buprenorphine.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector